Brokerage Firm Rating Update on Amarin Corporation PLC (AMRN)

Amarin Corporation PLC (AMRN) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 3 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Amarin Corporation PLC (AMRN) : Average target price received by Amarin Corporation PLC (AMRN) is $6.83 with an expected standard deviation of $2.84. The most aggressive target on the stock is $10, whereas the most downbeat target is $5. 3 financial analysts are currently covering the stock.


For the current week, the company shares have a recommendation consensus of Buy.

Amarin Corporation PLC (NASDAQ:AMRN): The stock opened at $3 and touched an intraday high of $3.17 on Wednesday. During the day, the stock corrected to an intraday low of $2.97, however, the bulls stepped in and pushed the price higher to close in the green at $3.13 with a gain of 4.68% for the day. The total traded volume for the day was 5,780,569. The stock had closed at $2.99 in the previous trading session.

Amarin Corporation plc (Amarin) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarins lead product, Vascepa (icosapent ethyl) capsules, are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (triglyceride or TG over 500 milligrams per deciliter) hypertriglyceridemia. The Company sells Vascepa principally to various wholesalers, as well as regional wholesalers and specialty pharmacy providers, who in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. Vascepa is available in the United States by prescription only. Amarin is also developing Vascepa for the treatment of patients with high (TG over 200 milligrams per deciliter and less than 500 milligrams per deciliter) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.